小儿支气管哮喘的T淋巴细胞亚群测定

支气管哮喘(下称支喘)病人的T淋巴细胞亚群的测定,国外学者已有不少报道,国内也已开展这项工作。为了了解本地区支喘患儿的T淋巴细胞亚群的状况,以探讨其在支喘的发病机制中的作用,本文采用卫生部武汉生物制品研究所生产的抗人淋巴细胞及其亚群的单克隆抗体,测定支喘发作期患儿的     

脐血造血干细胞移植治疗重型β地中海贫血1例

脐血造血干细胞移植治疗重型β地中海贫血１例①黄绍良１方建培１周敦华１陈纯１吴祥元３朱为国４梁晓燕２李树浓２（中山医科大学１孙逸仙纪念医院儿科；广州，５１０１２０２病生教研室３附属第三医院内科４第一军医大学南方医院儿科）主题词β地中海贫血／治；造血干细...     

人脐血及外周血CIK、NKT及NK细胞含量及意义

[目的]了解人脐血(CB)及不同来源外周血(PB)CIK细胞、NKT细胞和NK细胞的分布规律.[方法]通过流式细胞术检测不同来源标本中CD3 CD56 CIK细胞、Vα24 CD161 NKT细胞和CD3-CD56 NK细胞的比例,比较上述细胞分布的差异性.[结果]CB中CIK细胞、NK细胞的比例分别为1.37%±0.51%、7.07%±3.63%,均显著低于正常学龄前儿童外周血(C阳)及成人外周血(APB)(P＜0.01);而NKT细胞在CB、CPB和APB中比例均低,且三组间无显著性差异.[结论]CB中的抗肿瘤免疫效应细胞CIK细胞、NKT细胞及NK细胞含量均低,其中CIK细胞、NK细胞比例显著低于PB.     

人脐血T、B淋巴细胞和NK细胞的免疫学表达特性

目的 探讨人脐血T、B淋巴细胞和NK细胞，以及T／NK细胞杀伤性抑制性受体（KIR）表达的免疫学特性及其意义。方法 应用流式细胞仪检测26例正常新生儿脐血的T、B淋巴细胞和NK细胞抗原标记，包括CD45RA、CD45RO、CD69、CD25、CD40L、CD40、CD10、CD20和CD16等抗原的表达，以及脐血T／NK细胞上KIR分子（CD158a和CD158b抗原）的表达，并与正常儿童外周血比较。结果 脐血T淋巴细胞中CD45RA^ 细胞表达高于外周血（P＜0．01），CD45RO^ 则明显低于外周血（P＜0．01）；脐血T细胞CD69表达极低；CD25在CD8^ 细胞亚群中几乎不表达；CD40L在脐血T细胞中表达低于外周血（P＜0．05）。脐血B淋巴细胞中不成熟亚群CD10^ ／CD19^ 比例增高，成熟B细胞表型CD19、CD20、CD40等抗原均明显高于正常外周血（P＜0．01）。脐血中T淋巴细胞和NK细胞均存在KIR分子表达；脐血和外周血中T淋巴细胞CD158分子表达低于NK细胞（P＜0．01），脐血T淋巴细胞亚群中CD158分子表达低于正常外周血；CD158几乎不表达于CD4^ T细胞，主要表达于CD8^ T细胞，且以CD158a^ 为主；脐血中NK细胞CD158分子表达高于T淋巴细胞（P＜0．05），但明显低于外周血NK细胞KIR的表达（P＜0．01）。结论 脐血T淋巴细胞包括原始和早期T细胞以及T细胞受体表达障碍，导致脐血T淋巴细胞免疫功能不成熟，可能是脐血移植（UCBT）后移植物抗宿主病（GVHD）发生率低和程度轻的重要原因之一。脐血B淋巴细胞免疫应答障碍可能缘于T淋巴细胞表型或功能的障碍。脐血T／NK细胞KIR的表达特性提示，KIR可能与UCBT中GVHD和移植物抗白血病（GVL）效应有关。     

左旋门冬酰胺酶治疗儿童恶性肿瘤的毒副作用及其防治研究

目的　探讨左旋门冬酰胺酶 (L ASP)化疗的毒副作用及可行的防治方法。方法　回顾分析 139个疗程L ASP的使用 ,比较曾使用预防某种毒副作用措施的疗程及未使用预防该毒副作用措施的疗程的毒副作用发生率 ,分析防治措施的有效性。结果　 139个疗程中 4 4个疗程产生如下毒副作用 :凝血障碍、过敏、急性胰腺炎、消化道反应、糖尿病、低蛋白血症、高脂血症。 5例患儿因L ASP毒副作用死亡。给予预防措施疗程和无预防措施疗程毒副作用发生率的差异有显著性意义。结论　积极预防可减少L ASP毒副作用 ,保证化疗顺利进行 ;及时诊断和处理L ASP毒副作用可减少严重合并症的发生 ,提高患儿的生存质量     

癫痫发作过程海马区脑源性神经营养因子及其相关蛋白的变化

目的:探讨脑源性神经营养因子(BDNF)与癫痫发作的关系。方法:将听源性癫痫鼠分成安静期、惊厥前期、惊厥期及惊厥后期4组,用免疫组织化学方法检测在惊厥不同阶段脑内海马区BDNF及相关蛋白,用图像分析仪比较各蛋白的阳性单位(PU)。Wistar大鼠作对照。结果:听源性癫痫鼠安静期BDNF显著低于对照组,受刺激兴奋后的惊厥前期、惊厥期及惊厥后期BDNF增高并略高于对照组;而BDNF受体(trkB)的表达在各阶段均增高,作为trkB激活的标志蛋白磷酸化酪氨酸(PY20)只在受刺激兴奋后的惊厥前期和惊厥期增高;具抑制性作用的神经肽(NPY)在惊厥前均处于低水平。结论:内源性BDNF可能分别通过调控NPY和激活受体trkB两个途径影响听源性癫痫鼠的神经兴奋性。     

新生儿红细胞6-磷酸葡萄糖脱氢酶缺乏症中性粒细胞四唑氮蓝还原试验的观察

1968年Park等采用四唑氮蓝(NBT)试验作为急性感染的辅助诊断,继后发现部分红细胞6-磷酸葡萄糖脱氢酶(G-6PD)缺乏者的白细胞功能有异常,NBT还原率低。我们于1975年10月～1977     

间充质干细胞治疗糖皮质激素耐药性慢性移植物抗宿主病临床疗效观察

Objective To assess whether treatment with mesenchymal stem cells (MSCs) is an effective adjunct therapy for refractory extensive chronic graft-versus-host disease (GVHD) resistant to conventional therapy. Methods 12 patients with steroid-resistant extensive chronic GVHD were treated with MSCs. One patient received one dose, 10 received two doses, and the remaining three doses. The MSCs were obtained from HI,A-identical sibling donors (n = 14), haploidentical donors (n = 2), unrelated mismatched donor (n = 1) and third-party HLA-mismatched donors (n = 7). Of the 11 patients treated with multiple infusions, 5 received cells derived from two donors. The median first dose of MSCs was 1.0 (0. 4-2. 1) × 106/kg , the median second dose was 1.2(0. 8-1.9) × 106/kg , and the third dose in one patient was 1.1 × 106/kg. Meanwhile the proportion of CD3+ ,CD4+,CD8+ ,CD19+,CD4+ CD25+ ,FOXP3+,FOXP3+CD4+ and FOXP3+ CD25+ was determined with double fluorescent-labeled antibodies and flow cytometry before and 4 weeks after the MSCs infusion. Results No patients had side-effects during or immediately after the infusions of MSCs. After a treatment course of one to three doses, 3 patients had complete response(CR), 6 showed partial response(PR) and 3 did not respond; the total effective rate was 75% (9/12). Complete resolution was seen in the involvement of skin (3/12), lung (1/3), joints (1/5), liver (3/10), oralcavity (4/12) and eye (2/7). Response rate was not related to donor HLA-match. 3 CR patients discontinued all of the immunosuppressive agents without relapse 100 to 292 days after the MSC infusion and 6 PR patients taped all immunosuppressive agents after 60 to 79 days. Mean follow-up period was 1152(795-1914) days, leukemia free survival rate was 91.7% (11/12) and the overall survival rate was 75% (9/12). The ratio of CD4/CD8 and the proportion of regulatory T cells were significantly higher than that before MSCs treatment. Conclusion Third-party MSCs were as effective as HLA-identical or haploidentical cells. This finding has practical implications and suggests that third-party cells can be prepared and stored frozen to be used for steroid-resistant extensive chronic GVHD therapy. It is concluded that MSCs may prevent the lethal cGVHD after allogeneic hematopoietic stem cell transplantation and raise the survival rate by increasing the ratio of CD4/CD8 and proportion of regulatory T cells in vivo.